Why the study?
To evaluate the efficacy and safety of ofatumumab compared with teriflunomide specifically in recently diagnosed, treatment-naive participants from the ASCLEPIOS trials.
Does ofatumumab reduce annualized relapse rate and disability worsening in recently diagnosed, treatment-naive patients with relapsing multiple sclerosis compared to teriflunomide?
Does ofatumumab reduce annualized relapse rate and disability worsening in recently diagnosed, treatment-naive patients with relapsing multiple sclerosis compared to teriflunomide?
Ofatumumab significantly reduces annualized relapse rate and delays disability worsening compared to teriflunomide in recently diagnosed, treatment-naive patients with relapsing multiple sclerosis.
Answers are grounded in this paper and cite their sources.
Supports first-line ofatumumab in recently diagnosed treatment-naive RMS; extends ASCLEPIOS superiority to this early untreated subgroup.
Background: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving teriflunomide. Objectives: To assess the efficacy and safety of ofatumumab versus teriflunomide in recently diagnosed, treatment-naive (RDTN) participants from ASCLEPIOS. Methods: Participants were randomized to receive ofatumumab (20 mg subcutaneously every 4 weeks) or teriflunomide (14 mg orally once daily) for up to 30 months. Endpoints analysed post hoc in the protocol-defined RDTN population included annualized relapse rate (ARR), confirmed disability worsening (CDW), progression independent of relapse activity (PIRA) and adverse events. Results: Data were analysed from 615 RDTN participants (ofatumumab: n = 314; teriflunomide: n = 301). Compared with teriflunomide, ofatumumab reduced ARR by 50% (rate ratio (95% confidence interval (CI)): 0.50 (0.33, 0.74); p < 0.001), and delayed 6-month CDW by 46% (hazard ratio (HR; 95% CI): 0.54 (0.30, 0.98); p = 0.044) and 6-month PIRA by 56% (HR: 0.44 (0.20, 1.00); p = 0.049). Safety findings were manageable and consistent with those of the overall ASCLEPIOS population. Conclusion: The favourable benefit–risk profile of ofatumumab versus teriflunomide supports its consideration as a first-line therapy in RDTN patients. ASCLEPIOS I and II are registered at ClinicalTrials.gov (NCT02792218 and NCT02792231).
No takes yet. Share an insight, caveat, or question.
Gärtner et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: